Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.49 Mil Enterprise Value: 126.67 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 52/100

Lexicon Pharmaceuticals Inc RELIEF-PHN-1 Call Transcript

Dec 21, 2022 / 10:00PM GMT
Release Date Price: €4.1
Operator

Good day, and welcome to the Lexicon Pharmaceuticals Inc. top line results for LX9211 from the RELIEF-PHN-1 trial conference call. (Operator Instructions) . After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Mr. Jeff Wade. Please go ahead, sir.

Jeffrey L. Wade
Lexicon Pharmaceuticals, Inc. - President & CFO

Good afternoon. I'm Jeff Wade, Lexicon's President and Chief Financial Officer. And joining me on the call today are Lonnel Coats, Lexicon's Chief Executive Officer; and Dr. Craig Granowitz, our Senior Vice President and Chief Medical Officer. Earlier this afternoon, we issued a press release announcing top line results of our RELIEF-PHN-1 Phase II study of LX9211 in postherpetic neuralgia. A webcast of this call, along with the slide presentation is available on our website. And during this call, we will review the information provided in the press release and then use the remainder of our time to answer your questions.

Before

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot